The following table represents example categories to consider in describing your current results/status and desired results at the end of the funding period.
*/
Category
Parameters
Structure/Identity
Vector backbone, Transgene, Serotype, promoter, reagent purity achieve etc
In vitro activity
Treatment effect size on mRNA, protein expression, and dose response
Selectivity/off-target effect to related target
Selectivity to broader targets
Selectivity/off-target effect to related target
Selectivity to broader targets
Target tissue/cell biodistribution
and expression/tropism
and expression/tropism
Short-term distribution
Short-term expression (mRNA/Protein)
Long-term distribution
Long-term expression (mRNA/protein)
Short-term expression (mRNA/Protein)
Long-term distribution
Long-term expression (mRNA/protein)
In vivo activity (such as target
engagement/proximal downstream effect
or efficacy) Indicate dose and route of administration
engagement/proximal downstream effect
or efficacy) Indicate dose and route of administration
Concentrations of testing agent in the serum and target tissue
Brain penetration
Serum half-life, AUC or other pharmacokinetic properties
Optimize Dose Selection and Schedule
ED50, Minimal effective dose, and Optimal effective dose
Treatment duration optimization
Treatment window optimization
Interactions with standard of care
Selectivity/off-target effect in vivo
Brain penetration
Serum half-life, AUC or other pharmacokinetic properties
Optimize Dose Selection and Schedule
ED50, Minimal effective dose, and Optimal effective dose
Treatment duration optimization
Treatment window optimization
Interactions with standard of care
Selectivity/off-target effect in vivo
Safety
Tolerability
Antibodies to virus or gene product
T-cell response
Tumorigenesis
Antibodies to virus or gene product
T-cell response
Tumorigenesis
CMC
Master/Working Virus Bank Status
Process development status
Analytical Assays for release testing with specifications
Scale-up feasibility
Formulation needs/development
Stability Analysis
Potency assays (in vitro/in vivo)
Delivery devices
Process development status
Analytical Assays for release testing with specifications
Scale-up feasibility
Formulation needs/development
Stability Analysis
Potency assays (in vitro/in vivo)
Delivery devices
GLP analytical method development/validation
Potency assays, assays for purity, pharmacokinetics and pharmacodynamics etc
Interactions with regulatory agencies
Pre-Pre-IND
Pre-IND
Pre-IND
Patent protection?
Reference to consider when preparing you application and managing your project:
Cheever, Thomas et al. Perspectives on Best Practices for Gene Therapy Programs. Hum Gene Ther. 2015 Mar 1; 26(3): 127–133.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4367233/